Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Both companies have been selected for stand-by production by German government
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
